TY  - JOUR
AU  - Espinosa-Oliva, Ana M
AU  - Garcia-Miranda, Pablo
AU  - Alonso-Bellido, Isabel Maria
AU  - Carvajal, Ana E
AU  - Gonzalez-Rodriguez, Melania
AU  - Carrillo-Jimenez, Alejandro
AU  - Temblador, Arturo J
AU  - Felices-Navarro, Manuel
AU  - Garcia-Dominguez, Irene
AU  - Roca-Ceballos, Maria Angustias
AU  - Vazquez-Carretero, Maria D
AU  - Garcia-Revilla, Juan
AU  - Santiago, Marti
AU  - Peral, Maria J
AU  - Venero, Jose Luis
AU  - de-Pablos, Rocio M
PY  - 2021
DO  - 10.3389/fphar.2021.706439
SN  - 1663-9812
UR  - http://hdl.handle.net/10668/18495
T2  - Frontiers in pharmacology
AB  - Parkinson's disease is a highly prevalent neurological disorder for which there is currently no cure. Therefore, the knowledge of risk factors as well as the development of new putative molecular targets is mandatory. In this sense, peripheral...
LA  - en
PB  - Frontiers Research Foundation
KW  - Parkinson’s disease
KW  - galectin-3
KW  - microglia
KW  - neuroinflammation
KW  - peripheral inflammation
KW  - Galectin 3
KW  - Microglia
KW  - Neuroinflammatory Diseases
KW  - Lipopolysaccharides
KW  - Dextrans
KW  - sodium sulfate
KW  - Parkinson Disease
KW  - Inflammation
KW  - Risk Factors
KW  - Colon
TI  - Galectin-3 Deletion Reduces LPS and Acute Colitis-Induced Pro-Inflammatory Microglial Activation in the Ventral Mesencephalon.
TY  - research article
VL  - 12
ER  -